Volume 29, Number 1—January 2023
Online Report
Efficiency of Field Laboratories for Ebola Virus Disease Outbreak during Chronic Insecurity, Eastern Democratic Republic of the Congo, 2018–2020
Table 1
Type of setup, activities, and sites in field laboratories for EVD outbreak, eastern Democratic Republic of the Congo, 2018–2020*
Type of laboratory setup | Activities performed | Sites/provinces |
---|---|---|
Basic |
EVD diagnosis: GeneXpert (+)†; Chemistry: Piccolo (+/–)‡ |
Tchomia/Ituri, Bunia/Ituri, Tchowe/South-Kivu Bukavu/South-Kivu, Biakato/Ituri, Kasindi/North-Kivu |
Standard§ |
EVD diagnosis: GeneXpert (+); Chemistry: Piccolo (+); Hematology: pocH-100i (+)¶; Ebola survivors clinic |
Mangina/North-Kivu, Goma/North-Kivu, Komanda/Ituri, Mambasa/Ituri |
Advanced§ | EVD diagnosis: GeneXpert (+); Chemistry: Piccolo (+); Hematology: pocH-100i; Ebola survivors clinic; EVD differential diagnosis (Smart cycler or RPA) (+) or genomic sequencing (+) |
Beni/North-Kivu, Butembo/North-Kivu, Katwa/North-Kivu |
*EVD, Ebola virus disease; RPA, recombinase polymerase amplification. †GeneXpert, (Cepheid, https://www.cepheid.com). ‡Abaxis (https://www.abaxis.com). §Sysmex (https://www.sysmex.com). ¶Research support: Ebola therapeutics through a Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) protocol or the Pamoja Tulinde Maisha/Together save lives (PALM) randomized controlled trial; the immunogenicity of rVSV-ZEBOV-GP vaccine; and the study of Ebola virus reservoir in bats.
Page created: November 30, 2022
Page updated: December 22, 2022
Page reviewed: December 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.